| Literature DB >> 31199910 |
Abstract
An "off-the-shelf" cell therapy derived from induced pluripotent stem cells (iPSCs) has entered clinical trials in the United States. Other companies are following suit, harnessing iPSCs' self-renewal ability to manufacture cell therapies that don't require customization for each patient. But some experts aren't sure such therapies are a good idea.Entities:
Mesh：
Year: 2019 PMID： 31199910 DOI： 10.1016/j.cell.2019.05.043
Source DB: PubMed Journal: Cell ISSN： 0092-8674 Impact factor: 41.582